Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT02613208
- Locations
- 🇪🇸
Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain
🇪🇸Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, La Coruna, LA Coruña, Spain
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: Observational ChemotherapyDrug: Concomitant Bevacizumab
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 765
- Registration Number
- NCT02612077
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT02611323
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
🇮🇹SCDU Ematologia, Novara, Piemonte, Italy
Accu-Chek® CONNECT at School (CATS) Pediatric Study
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: DMSDevice: Accu-Chek® CONNECT DMS
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 196
- Registration Number
- NCT02609633
- Locations
- 🇺🇸
Pediatric Endocrinology of Phoenix, Phoenix, Arizona, United States
🇺🇸Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
🇺🇸Nemours Childrens Hospital, Pensacola, Florida, United States
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT02611310
- Locations
- 🇸🇦
National Guard King Abdulaziz Medical City; Oncology, Riyadh, Saudi Arabia
🇸🇦King Abdullah Medical City-Holy Makkah, Holy Makkah, Saudi Arabia
🇸🇦King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 291
- Registration Number
- NCT02608112
- Locations
- 🇫🇷
Hopital Jean Minjoz, Besancon, France
🇫🇷CH de Saint Quentin, Saint Quentin, France
🇫🇷Cabinet de Rhumatologie MSP de Beaublanc, Limoges, France
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02608073
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT02608060
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
- Conditions
- HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT02605915
- Locations
- 🇺🇸
HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸Horizon Oncology Research, Inc., Lafayette, Indiana, United States
🇺🇸St. Luke's University Health Network, Bethlehem, Pennsylvania, United States
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT02604342
- Locations
- 🇮🇹
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy
🇵🇱Medical University of Gdansk, Gdansk, Poland
🇮🇹Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy